Press Releases

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

Aptamer Group and Mologic are working towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial laboratory tests have demonstrated excellent sensitivity, being able to detect as little as 1000 virus particles per mL, and further clinical validation to support the CE marking will be performed at the Integrated COVID Hub North East in Newcastle, UK. As it’s based on aptamers (synthetic nucleic acid-based affinity reagents) rather than standard protein-based affinity reagents, the test would offer significant cost advantages, allowing large scale development and delivery of tests globally, including to low- and middle-income countries.

Bioinformatics-Analysis Division Revised Website for Better User Experience

MicrobioSeq Releases Microecology and Cancer Solutions to Accelerate Your Cancer Research and Discovery

Irish Company Develops Cloud-Based App Aimed to Accelerate Global COVID-19 Vaccination Process

MICROSENSDX RapiPRO™ LAMP for SARS-CoV-2 RECEIVES CE MARK APPROVAL

BOC Sciences Provides Extensive Catalog of Building Blocks

MedAI Integrates Its Drug Research and Development Platform for the Pharmaceutical Industry

Thermo Fisher Scientific Collaborates with Artificial to Enhance COVID-19 Diagnostic Testing Solution

Thermo Fisher Scientific, which today announced their collaboration with Artificial to increase the productivity of COVID-19 testing through an integrated and comprehensive software automation platform.

Ceryx Medical appoints Chas Taylor as Chairman

Ceryx Medical, the business behind a revolutionary technology that could significantly change the way patients with serious heart problems are treated, has appointed Chas Taylor, a leading medical devices entrepreneur, as Chairman.

Creative BioMart Biomarker Released Multiple Biomarker Detection Service

Continuous manufacturing μLOT® enabling technology could cut pharma industry’s use of toxic chemicals by one hundred times

Speaking at the ‘Innovative Chemistry for Peptide Manufacturing and Analysis’ conference, SB3000’s Chief R&D Officer Jens Bukrinski revealed that continuous manufacturing μLOT® technology could reduce the pharmaceutical industry’s use of toxic chemicals by 100 times.

Lifeasible Updated Its Animal Metabolomics Analysis Service

Formulationbio Newly Launches Disintegrant Excipients for Pharmaceutical Preparation

SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, has announced a collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

RegDesk Launches ‘Dash 2.0’ to Improve Medical Device Applications

RegDesk, a regulatory approval software company, has released an updated version of its 'Dash' platform for device manufacturers.

Matexcel Offers a Comprehensive List of Graphene Products

Creative Biostructure Provides Various Vaccine Development Services for Coronavirus

Profacgen Provides Immunogenicity Testing Services to Help with Drug Discovery and Development

Albumedix announces recombinant human albumin supply partnership with FUJIFILM Wako Pure Chemical Corporation for the Japanese, Chinese and Hong Kong markets

Albumedix Ltd., an enabler of advanced therapies and world leader in recombinant human albumin, has announced a new distribution partnership with FUJIFILM Wako Pure Chemical Corporation (FUJIFILM Wako), to advance therapy and biopharmaceutical development in Japan and China including Hong Kong.

Alfa Chemistry Catalysts Launches Catalysts for Olefin Metathesis Reaction